Amgenvs.Neurocrine Biosciences
AMGN vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 15× larger than Neurocrine Biosciences by market cap; Neurocrine Biosciences trades at the lower P/E (22.0 vs 25.8); year to date, Amgen leads (+35.6% vs +7.9%).
Side by side
| AMGN | NBIX | |
|---|---|---|
| Market cap | $226B | $15.5B |
| Price | $442.24 | $153.37 |
| Today | −0.4% | +0.2% |
| Return YTD | +35.6% | +7.9% |
| Return 1Y | +51.1% | +13.0% |
| P/E | 25.8 | 22.0 |
| P/S | 5.9 | 4.6 |
| P/B | 19.3 | 4.2 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →Neurocrine BiosciencesNBIX
Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.
Full NBIX profile →More AMGN & NBIX comparisons
Other head-to-heads in the Biotech & innovation segment.
See where AMGN and NBIX sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →